BridgeBio Pharma, Inc.

Name: BridgeBio Pharma, Inc. standardized financial statements, quarterly
Creator: Listed

BBIONasdaqCIK 1743881HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$353.2m, Q3 FY2026

Operating income−$11.6m, Q3 FY2026

Net income−$56.7m, Q3 FY2026

BridgeBio Pharma, Inc., income statement, quarterly
Line item	Unit	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Revenue	$m	1.7	211	2.2	2.7	5.9	117	111	121	154	195	244	353
Cost of revenue	$m	0.6	0.6	0.6	0.6	2.1	2.6	3.7	6.6	8.1	9.9	15.0	20.5
Research and development	$m	130	141	115	120	130	111	111	113	116	127	149	144
Selling, general and administrative	$m	47.6	65.8	59.5	68.8	94.8	106	129	138	158	164	186	201
Operating income	$m	(177)	0.3	(176)	(192)	(226)	(104)	(134)	(145)	(140)	(106)	(107)	(11.6)
Interest expense	$m	20.3	23.5	22.9	23.1	21.5	18.1	11.6	11.7	11.6	12.9	13.3	13.3
Income tax	$m	0.0	0.0	0.0	0.0	1.2	0.0	2.1	(1.5)	(0.1)	not reported	0.0	1.2
Net income	$m	(170)	(36.2)	(75.5)	(164)	(267)	(170)	(184)	(183)	(201)	(167)	(156)	(56.7)
Diluted EPS	$ per share	not reported	(0.20)	(0.39)	(0.86)	not reported	(0.88)	(0.95)	(0.95)	not reported	(0.84)	(0.78)	(0.42)
Basic EPS	$ per share	not reported	(0.20)	(0.39)	(0.86)	not reported	(0.88)	(0.95)	(0.95)	not reported	(0.84)	(0.78)	(0.42)

Balance sheet

Cash and equivalents$1.53bn, Q3 FY2026

Long-term debt$2.63bn, Q3 FY2026

Shareholders' equity−$1.66bn, Q3 FY2026

BridgeBio Pharma, Inc., balance sheet, quarterly
Line item	Unit	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Cash and equivalents	$m	376	475	408	266	681	541	749	643	570	880	678	1,533
Current assets	$m	478	783	616	445	721	695	912	839	798	1,241	1,093	2,045
Total assets	$m	546	849	794	665	919	882	1,080	998	936	1,371	1,217	2,162
Current liabilities	$m	144	141	134	139	154	152	176	217	288	816	891	977
Total liabilities	$m	1,889	1,886	1,876	1,883	2,377	2,520	2,859	2,921	3,013	3,640	3,723	3,815
Long-term debt	$m	446	435	435	436	437	0.0	0.0	2,007	2,007	2,653	2,653	2,630
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	(1,354)	(1,050)	(1,093)	(1,230)	(1,468)	(1,648)	(1,788)	(1,933)	(2,087)	(2,278)	(2,515)	(1,662)

Cash flow

Operating cash flow−$44.2m, Q3 FY2026

Capital expenditure$290.0k, Q3 FY2026

Share repurchases$42.5m, Q3 FY2026

BridgeBio Pharma, Inc., cash flow, quarterly
Line item	Unit	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Operating cash flow	$m	(125)	(220)	74.7	(181)	(195)	(199)	(80.7)	(110)	(56.4)	(197)	(71.1)	(44.2)
Capital expenditure	$m	0.4	0.7	0.1	0.1	0.0	0.0	0.6	0.5	0.0	0.1	0.4	0.3
Dividends paid	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Share repurchases	$m	not reported	0.0	0.0	0.0	0.0	48.3	0.0	0.0	0.0	82.5	128	42.5

Diluted shares (weighted)196.03m, Q3 FY2026

BridgeBio Pharma, Inc., shares, quarterly
Line item	Unit	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Diluted shares (weighted)	m shares	153	161	163	179	188	189	190	191	192	195	196	196

Shares outstanding: 194.80m at Oct 22, 2026, from the cover of the 10-Q filed Oct 29, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 19:20 ET. Listed shows no prices and gives no investment advice.